Location
United States, North America
Check Size
$100K - $10M
Investment Stage
Series A
Focus Areas
BioTech
Pharmaceuticals
About Investor
Chris Garabedian is the CEO of Xontogeny and Portfolio Manager at Perceptive Advisors’ PXV Fund, specializing in life sciences. He invests between $100K and $10.0M, with a focus on biotech and pharmaceuticals at Series A stage. Based between New York City and Boston, he brings decades of experience as a biotech executive and investor.
Previous investments
PolyCore Therapeutics
2022
VivoSense
25M |2022
Zucara Therapeutics
20M |2024
21M |2020
Similar Investors
AL
Abdul Ly
United States, North America
$1M - $4M
Seed
,Series A
,PS
Paul Straub
United States, North America
$100K - $2M
Pre Seed
,Seed
,RF
Riley Florsheim
United States, North America
$100K - $5M
Pre Seed
,Seed
,DG
Danielle Graham
Canada, North America
$100K - $300K
Pre Seed
,Seed
,JR
JJ Richa
United States, North America
$50K - $1M
Pre Seed
,Seed
,AL
Alicia Lenis
Canada, North America
$500K - $2M
Pre Seed
,Seed
,Is this You?
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Grow with the Right Investors
This profile is just one example. Our AI matches you with the investors who best fit your stage, industry, and vision.
Start Matching For Free